PRAX reports extended runway with $926M cash balance

PARAGRAPH 1 --- What happened: Praxis Precision Medicines (PRAX) extended its cash runway significantly, reporting a $926 million cash balance as of December 31, 2025. This was driven by a $621 million financing round in January 2025. Separately, ADC Therapeutics (ADCT) reported $73.6 million in revenue for 2025, with a cash runway extending into 2028.

PARAGRAPH 2 --- Market impact: This narrative impacts biotechnology and healthcare sectors, specifically companies with late-stage clinical assets. PRAX's extended runway allows it to fund operations and clinical trials, potentially driving share price appreciation. ADCT's strong financials and extended runway boost confidence in the sector, benefiting similar companies.

PARAGRAPH 3 --- What to watch next: Investors should monitor PRAX's cash balance evolution, with key updates expected in its Q1 2026 earnings report (scheduled for May 15, 2026). Additionally, watch for FDA decisions on PRAX's lead product, PRAX-114, expected in Q4 2026, and ADCT's ZYNLONTA, expected in Q2 2026. These regulatory decisions could significantly impact both companies' share prices.